Characterization of Foxp3 IL-10-Secreting CD4 + + CD4

This information is current as of June 20, 2018. Characterization of Foxp3 IL-10-Secreting CD4 + + CD4 CD25 + + CD25 + and T Cells during Cure of Colitis Holm H. Uhlig, Janine Coombes, Christian Mottet, Ana Izcue, Claire Thompson, Andrea Fanger, Andrea Tannapfel, Jason D. Fontenot, Fred Ramsdell and Fiona Powrie J Immunol 2006; 177:5852-5860; ; doi: 10.4049/jimmunol.177.9.5852 http://www.jimmunol.org/content/177/9/5852 References Subscription Permissions Email Alerts This article cites 45 articles, 22 of which you can access for free at: http://www.jimmunol.org/content/177/9/5852.full#ref-list-1 Why The JI? Submit online. Rapid Reviews! 30 days* from submission to initial decision No Triage! Every submission reviewed by practicing scientists Fast Publication! 4 weeks from acceptance to publication *average Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/about/publications/ji/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts Downloaded from http://www.jimmunol.org/ by guest on June 20, 2018 The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.

The Journal of Immunology Characterization of Foxp3 CD4 CD25 and IL-10-Secreting CD4 CD25 T Cells during Cure of Colitis 1 Holm H. Uhlig, 2 * Janine Coombes, 2 * Christian Mottet,* Ana Izcue,* Claire Thompson,* Andrea Fanger, Andrea Tannapfel, Jason D. Fontenot, Fred Ramsdell, and Fiona Powrie 3 * CD4 CD25 regulatory T cells can prevent and resolve intestinal inflammation in the murine T cell transfer model of colitis. Using Foxp3 as a marker of regulatory T cell activity, we now provide a comprehensive analysis of the in vivo distribution of Foxp3 CD4 CD25 cells in wild-type mice, and during cure of experimental colitis. In both cases, Foxp3 CD4 CD25 cells were found to accumulate in the colon and secondary lymphoid organs. Importantly, Foxp3 cells were present at increased density in colon samples from patients with ulcerative colitis or Crohn s disease, suggesting similarities in the behavior of murine and human regulatory cells under inflammatory conditions. Cure of murine colitis was dependent on the presence of IL-10, and IL-10- producing CD4 CD25 T cells were enriched within the colon during cure of colitis and also under steady state conditions. Our data indicate that although CD4 CD25 T cells expressing Foxp3 are present within both lymphoid organs and the colon, subsets of IL-10-producing CD4 CD25 T cells are present mainly within the intestinal lamina propria suggesting compartmentalization of the regulatory T cell response at effector sites. The Journal of Immunology, 2006, 177: 5852 5860. Increasing evidence suggests that functionally specialized subsets of CD4 T cells play a key role in the regulation of immune responses (1, 2). In particular, naturally occurring CD4 CD25 regulatory T cells (T R ) 4 have been shown to prevent both T cell-mediated and innate immune pathology in a number of disease models (3 5). CD4 CD25 T R cells with similar properties to those described in mice are also present in humans and impaired function of these cells has been observed in patients with autoimmune disease (6 11). The transcription factor Foxp3 is differentially expressed by CD4 CD25 T R cells and plays a key role in their development and function (12 14). Accordingly, mice lacking functional Foxp3 develop a multiorgan-inflammatory disease (12, 15, 16). Similarly, loss of function mutations in FOXP3 have been shown to be responsible for the human autoimmune and inflammatory disease, immune polyendocrine X-linked enteropathy, providing evidence that T R cells also contribute to immune homeostasis in humans (17, 18). The T cell transfer model of colitis provides a good system with which the mechanisms of T R function can be dissected. In this *Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom; Children s Hospital and Institute of Pathology, University of Leipzig, Leipzig, Germany; Department of Immunology, University of Washington, Seattle, WA 98195; and Zymogenetics, Seattle, WA 98102 Received for publication February 22, 2006. Accepted for publication August 3, 2006. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by the Wellcome Trust (to F.P. and C.T.), the Medical Research Council (to J.C.), Deutsche Forschungsgemeinschaft Grant HU 128-2 (to H.H.U.), the University of Leipzig (to H.H.U., F1-49), the Swiss National Fund (to C.M.), training grants from the National Institutes of Health and the Cancer Research Institute, and the Spanish Ministerio de Educacion y Ciencia (to A.I.). 2 H.H.U. and J.C. contributed equally. 3 Address correspondence and reprint requests to Dr. Fiona Powrie, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, U.K. E-mail address: fiona.powrie@pathology.ox.ac.uk 4 Abbreviations used in this paper: T R, regulatory T cell; IBD, inflammatory bowel disease; MLN, mesenteric lymph node; LP, lamina propria; CD, Crohn s disease; UC, ulcerative colitis; POD, peroxidase; MHC-II, MHC class II; DAPI, 4,6 -diamidino-2-phenylindole. model, transfer of naive CD4 CD45RB high T cells into immunodeficient mice leads to a Th1-mediated colitis, while cotransfer of CD4 CD25 T R cells can completely prevent disease (4). In addition, recent studies in models of type 1 diabetes and inflammatory bowel disease (IBD) have shown that CD4 CD25 T R not only prevent development of disease but can also actually reverse established inflammation (19 22). Thus, using the T cell transfer model of colitis, we found that CD4 CD25 T cells can reverse an established T cell-mediated inflammatory response in the intestinal mucosa by reducing the pathogenic T cell infiltrate, ultimately leading to restoration of normal intestinal architecture. It is likely that the mechanisms by which T R can prevent or cure colitis differ. In prevention of colitis, T R must control activation of a predominantly naive population of cells, while in cure of colitis, they must act on Ag-experienced cells and an aggressive inflammatory response. The ability of CD4 CD25 T R cells to resolve established inflammation in model systems raises the possibility that these cells may be useful as therapeutic agents for chronic inflammatory diseases in humans. With this in mind, it will be important to establish whether the properties of T R cells determined through study of prevention of colitis also apply to cure of colitis. Attempts to design effective therapeutic strategies will also be aided by knowledge of the location and behavior of T R in the human IBDs. We have previously shown that, during cure of experimental colitis, CD4 CD25 T cells proliferate and accumulate in the mesenteric lymph nodes (MLN) and also in the colonic lamina propria (LP). At both sites, the progeny of CD4 CD25 T cells are in direct contact with CD11c dendritic cells, as well as effector T cells (20). These findings suggest that regulation of an active immune response by CD4 CD25 T cells occurs in the draining lymph node, as well as at the site of inflammation. However, these studies have been limited by the lack of specific markers for naturally arising T R cells. Although useful, CD25 expression does not uniquely identify T R cells, as the CD4 CD25 pool can contain activated effector cells and not all T R cells express CD25. Identification of Foxp3 as a more specific marker for T R cells provides an opportunity to track the fate of T R cells in vivo Copyright 2006 by The American Association of Immunologists, Inc. 0022-1767/06/$02.00

The Journal of Immunology 5853 (23, 24), although studies to date have primarily focused on expression of Foxp3 mrna. Cure of colitis by CD4 CD25 T cells has also been shown to be functionally dependent on IL-10, however, it is not known whether T R cells themselves are the important source of IL-10 and where it is produced (19). In this study, we have used anti-foxp3 Abs together with analysis of IL-10 secretion to further investigate the functional and phenotypic characteristics of CD4 CD25 T cells under physiological conditions and during resolution of intestinal inflammation. Our results show that during cure of intestinal inflammation the majority of Foxp3 cells and IL-10-secreting cells derive from CD4 CD25 precursors. However, whereas Foxp3 cells are present in similar frequencies in both the secondary lymphoid organs and LP of colitic animals, IL-10-producing CD4 CD25 T cells selectively enrich within the colonic LP. In addition, we have extended these findings to analysis of human IBD and show an accumulation of Foxp3 CD4 CD25 cells in the inflamed intestine of patients with IBD. This suggests that chronic intestinal inflammation in humans is not simply a consequence of a lack of T R cells at the inflammatory site. Materials and Methods Mouse and human tissue samples BALB/cJ, C57BL/6J, congenic C57BL/6.SJL.CD45, C57BL/6 recombinase-activating gene 1-deficient (rag1 / ), CB17 SCID, IL-10-knockout (IL-10 / ), and Foxp3 / mice (12) were bred under specific pathogenfree conditions. All mice used were 6 wk old. Colonic tissue sections from patients with Crohn s disease (CD) and ulcerative colitis (UC) as well as inflamed and noninflamed human colon, appendix, and tonsil tissue were obtained from the Department of Pathology and from the Department of Ear Nose and Throat diseases of the University of Leipzig. All tissues were obtained for therapeutic and diagnostic reasons. The studies were approved by the local ethical review committee (HU242/04). Cell purification and flow cytometry CD4 T cell subsets were isolated from spleens as described (20). Essentially, erythrocyte-depleted spleen cell suspensions were enriched for CD4 cells by negative selection following incubation with anti-cd8 (clone YTS169 (25)), anti-b220 (clone RA3-6B2 (26)), anti-cd11b (clone TIB128; American Type Culture Collection (ATCC)) and anti-mhc-ii Abs (TIB120; ATCC). Ag-positive cells were depleted using sheep antirat-igg Dynal beads (Dynal Biotech). For MACS sorting of CD4 CD25 T cells, CD4 -enriched cells were incubated with biotinylated anti-cd25 (clone 7D4), followed by streptavidin MACS beads, and sorted on an AutoMACS (Miltenyi Biotec). For FACS sorting of CD4 CD45RB high and CD4 CD25 T cells, CD4 -enriched cells were stained with anti-cd45rb (clone 16A), anti- CD25 (clone 7D4), and anti-cd4 (clone H129.19; all BD Biosciences), and sorted on a MoFlo (DakoCytomation). The purity of MACS- and FACSsorted cells was 90 and 99%, respectively. Because similar results were obtained using MACS or FACS sorting, data were pooled. Unless otherwise stated, all Abs were obtained from BD Biosciences. FACS analysis of Foxp3 expression was performed using the Foxp3 staining kit from ebioscience. T cell transfer experiments SCID and rag1 / mice were injected i.p. with 4 10 5 syngeneic CD4 CD45RB high T cells. Mice developed colitis 3.5 4.5 wk posttransfer. Mice with clinical signs of disease were either sacrificed to assess the severity of colitis or received 10 6 CD4 CD25 T cells i.p., or no treatment. A further group of mice received weekly injections of 0.5 mg of anti-il-10r Ab (clone 1B1.2). Mice were observed daily and weighed weekly. All animal experiments were performed according to the home office guidelines and the United Kingdom Animals Scientific Procedures Act of 1986. Histology Tissue sections were stained with H&E and colitis severity was graded semiquantitatively from 0 to 4, as outlined in Ref. 27. Mouse tissue samples were snap-frozen and cryocut. Slides were acetone-fixed and blocked with donkey serum (Sigma-Aldrich). The endogenous peroxidase (POD) activity was inhibited using H 2 O 2, sodium azide, and in some cases glucose oxidase. Foxp3 staining was performed using rabbit polyclonal anti-mouse Foxp3 Abs (Celltech R&D) followed by FITC-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories). The Foxp3 staining was combined either with staining for CD4, CD25, MHC class II (MHC-II) or CD45.1 and 4,6 -diamidino-2-phenylindole (DAPI). Directly labeled anti-cd4-fitc (clone RM4-5; BD Biosciences) was used. Anti-CD25 (clone PC61) was detected using antimouse POD (Jackson ImmunoResearch Laboratories), and biotinylated anti- CD45.1 (A20; BD Biosciences) was detected using avidin-pod (Vector Laboratories). The POD activity was visualized by tyramide amplification (NEN Life Science Products) as described previously (20). Biotinylated anti-mhc-ii (I-A/I-E, clone 2G9) was detected using directly labeled streptavidin fluorescence conjugates (BD Biosciences). Some tissue sections were counterstained for 3 5 min with 0.1 1 g/ml DAPI (Sigma Aldrich). Fluorescence was detected using appropriate filter combinations for DAPI, FITC, Texas Red/Cy3, and Cy5. Human formalin-fixed paraffin-embedded tissue samples were deparaffinized, microwave pressure cooked to demask fixed Ags, and stained for CD3 (clone F7.2.38; DakoCytomation), and Foxp3 (rabbit polyclonal serum against human Foxp3; Celltech R&D) followed by anti-mouse or antirabbit POD-labeled Abs and routine POD staining. For costaining experiments, frozen tissue sections of human tonsil or appendix were cryocut, fixed in formalin, and incubated at 85 C in Ag retrieval buffer. After blocking the endogenous POD activity, sections were stained using mouse anti- CD4 (clone 1F6; Serotec) and donkey anti-mouse-pod (Jackson ImmunoResearch Laboratories) followed by tyramide amplification. After subsequent blocking of POD activity, Foxp3 was stained using polyclonal anti-foxp3 followed by donkey anti-rabbit-pod (Jackson ImmunoResearch Laboratories) and tyramide amplification. DAPI counterstaining was performed to visualize the tissue structure and to ensure the nuclear localization of the Foxp3 signal. Similarly, costaining for IL-10, CD3, and Foxp3 was performed using rat anti-il-10 (clone JES3-9D7; Caltag Laboratories), polyclonal anti-cd3 (A0452; DakoCytomation) and mouse anti- Foxp3 (clones 105/221D/D3 and 236A/E7; Abcam). Sections were subsequently incubated with appropriate donkey POD-labeled Abs (Jackson ImmunoResearch Laboratories) followed by tyramide amplification. Quantitative real-time PCR analysis Cells were FACS sorted to 99% purity and RNA extracted using the RNeasy minikit (Qiagen), including a DNase digestion step. cdna was transcribed with Superscript II (Invitrogen Life Technologies) and used as a template for real-time quantitative PCR. A multiplex reaction for CD3 and Foxp3 was preformed using the chromo4 (MJ Research) machine and results expressed relative to an arbitrary standard of CD4 T cell cdna. Foxp3 expression was then normalized to the internal standard, CD3. The following primers and TaqMan probe sequences were used: CD3 probe VIC-ACATAGGCACCATATCCGGCTTTATCTTCG-TAMRA; CD3 5 -TTACAGAATGTGTGAAAACTGCATTG; CD3 3 -CACCAAGAG CAAGGAAGAAGATG; Foxp3 probe FAM-ATCCTACCCACTGCTG GCAAATGGAGTC-TAMRA; Foxp3 5 -CCCAGGAAAGACAGCAAC CTT; Foxp3 3 -TTCTCACAACCAGGCCACTTG. Intracellular cytokine staining Cell suspensions were prepared from spleen, MLN, and the LP. For preparation of LP cell suspensions, colons were cut into 0.5-cm pieces and incubated in RPMI 1640 containing 10% heat-inactivated FCS and 5 mm EDTA for 15 min to remove epithelial cells. This step was performed in a shaking incubator at 37 C, and was repeated a further two times, with all supernatant being discarded. The remaining tissue was digested twice using RPMI 1640 containing 10% FCS, 15 mm HEPES, and 0.3 mg/ml Type II Collagenase/Dispase (Worthington Biochemical) for 1hina37 C shaking incubator. LP cells were collected and layered on a Percoll gradient (Amersham Biosciences) and centrifuged at 600 g for 20 min. The lymphocyte-enriched population was recovered from the 40 to 75% interface. Cell suspensions were stimulated with 100 ng/ml PMA and 1 g/ml ionomycin for4hinthepresence of 20 g/ml brefeldin A. After this in vitro stimulation, cells were stained for CD4 (clone H129.19) and CD45.1 (clone A20) followed by fixation in 2% paraformaldehyde and permeabilization in 0.5% saponin. This was followed by staining for intracellular IL-10 (clone JES5-16E3), IFN- (clone XMG1.2), or appropriate isotype controls (clones A95.1 and R3-34, respectively). For IL-10 and Foxp3 staining, cells were fixed in ebioscience Fix/Perm buffer after the in vitro stimulation. This was followed by permeabilization in 0.5% saponin and staining

5854 Foxp3 AND IL-10-SECRETING CD4 CD25 T R IN CURE OF COLITIS for IL-10 as indicated above. Finally, the cells were permeabilized in ebioscience buffer and stained for Foxp3 according to the manufacturer s instructions. Cells were analyzed using a FACSCalibur or FACSort (BD Biosciences). Statistics Two-tailed Mann-Whitney U test was performed using GraphPad Prism 3.00 (GraphPad). Values of p 0.05 were regarded as significant. Data are presented as mean SD. Results In situ distribution of Foxp3 CD4 CD25 T cells in wild-type mice Numerous studies have demonstrated that T R activity enriches within the CD4 CD25 subset, and this is consistent with its high level of expression of Foxp3. However, most studies have analyzed expression of Foxp3 mrna at the population level. The frequency of bona fide Foxp3 protein-expressing T R cells within the CD4 CD25 T cell pool and their distribution in vivo remain to be established. To investigate this, expression of CD25 was analyzed in combination with Foxp3 (Fig. 1). In tissue sections from spleen, MLN, and colon of wild-type mice, a minority of DAPI-stained cell nuclei also stained in a dotted pattern with the polyclonal rabbit anti-foxp3 serum (Fig. 1a). Control experiments using normal rabbit serum did not lead to any nuclear staining, FIGURE 1. Expression of Foxp3 by CD4 CD25 T cells in the lymphoid organs and colon of wild-type BALB/c mice. a, Wild-type MLN stained for Foxp3 and DAPI. b, Wild-type spleen and (c) Foxp3 / spleen stained for CD4 and Foxp3. d, Overview and (e) high power magnification of wild-type MLN stained for CD4, CD25, and Foxp3 and analyzed using laser-scanning microscopy. f i, Wild-type spleen (f), MLN (g), and colon (h) stained for Foxp3, CD25, and MHC-II and analyzed using conventional fluorescence microscopy. h and i show the same section of colon at different magnifications. j, Percentage of Foxp3 among CD25 cells (filled symbols) and Foxp3 among CD25 cells (open symbols) in the T cell area of spleen, MLN, and colon of BALB/c mice. The quantification is based on the approximate number of cells per area of lymphoid organ as indicated by the DAPI nuclear staining. Statistical significance was tested using the Mann-Whitney U test. Similar expression patterns of Foxp3 were found in spleen, MLN, and colon of C57BL/6 mice. k, Expression of Foxp3 mrna by splenic CD4 CD25 CD45RB low and CD4 CD25 CD45RB low T cells. Foxp3 mrna expression was normalized to CD3 expression. Data from RNA expression analysis of three independent FACS sorts were pooled. whereas the rabbit anti-histone H2B Ab stained all cell nuclei (data not shown). The specificity of the staining was further confirmed by the absence of nuclear staining in secondary lymphoid organs of Foxp3 / mice (Fig. 1, b and c). Foxp3 staining was found within a subpopulation of CD4 cells homogenously distributed in the T cells areas of secondary lymphoid organs. Furthermore, Foxp3 expression was largely associated with the expression of CD25 (Fig. 1, d j). Thus, 48 7 and 49 18% of CD25 cells were Foxp3 in the spleen or MLN, respectively. In contrast, only 0.7 0.2 and 0.6 0.4% of CD25 cells were Foxp3 (Fig. 1j). This enrichment of Foxp3 cells within the CD25 pool is in accordance with the mrna expression of these cells (Fig. 1k). The frequency of Foxp3 cells among CD25 cells in the colon, at 20 18%, was lower than in the spleen and MLN. Whether this represents a real reduction in the frequency of T R cells or is secondary to an increased frequency of activated CD4 CD25 T cells is not known. Costaining of CD25, Foxp3 and MHC-II indicated that 60 90% of CD25 Foxp3 cells were in contact with MHC-II cells (Fig. 1, f i), including in the intestine where they were preferentially contained within organized leukocytic clusters (Fig. 1, h and i). The presence of Foxp3 cells in colonic lymphoid structures argues for immunosuppressive activity of T R cells not only in the spleen and MLN, but also in the colon.

The Journal of Immunology In situ distribution of Foxp3 CD4 CD25 T cells during cure of colitis We next investigated the distribution of Foxp3 cells following cure of colitis by transfer of CD4 CD25 T cells. Colitis was induced in immune-deficient (C57BL/6J Rag / ) mice by transfer of wild-type (CD45.2 ) CD4 CD45RB high T cells. After development of the first signs of colitis, indicated by weight loss and diarrhea, a group of mice received a second transfer of congenic CD45.1 CD4 CD25 T cells. As previously described (20) this second transfer led to increased weight and resolution of colitis (Fig. 2). At the time of transfer, 90% of CD25 T cells expressed Foxp3 (data not shown). Two weeks after transfer of CD4 CD25 T cells, when colitis was still present, 50% of the CD45.1 progeny of the CD4 CD25 T cells expressed Foxp3 irrespective of whether spleen, MLN, or colon were analyzed (Fig. 2a and data not shown). Our data suggest that Foxp3 CD4 CD25 regulatory cells migrate not only to lymphoid organs but also into the inflamed LP. Following resolution of colitis, 5 10 wk after the secondary transfer of CD4 CD25 T cells, Foxp3 expression was still primarily restricted to the CD25 progeny and still detectable within 50% of these cells (Fig. 2b). Less than 2% of the CD4 CD45RB high progeny expressed Foxp3 at this time (n 4, data not shown), compared with 1% of donor CD45RB high T cells directly ex vivo (n 3, data not shown). Furthermore, in similar experiments performed in mice on the BALB/c background, we again saw no increase in the percentage of Foxp3 cells among the CD45RB high progeny. This suggests that cure of colitis in this model situation is not associated with the induction of Foxp3 in the progeny of CD4 CD45RB high T cells. Presence of Foxp3 IL-10 cells in the LP of the human colon The T cell transfer model of colitis reflects several features of the human IBDs, UC and CD. However, the human diseases present distinct histological morphology and are of heterogeneous pathogenicity. Consequently, we investigated the distribution of Foxp3 cells in human tissue. Within lymphoid organs, as well as in the appendix, Foxp3 expression was confined to the nuclei of CD4 and CD3 cells (Fig. 3, a and e) and present predominantly in the T cell areas. In tissue samples from noninflamed human colons, and in patients with intestinal inflammation, nuclear Foxp3-positive cells of lymphocyte morphology were present with the highest density in lymphoid follicles, although there were also scattered 5855 cells within the LP (Fig. 3b). The total number of Foxp3 cells was greater in inflamed tissue than in normal controls (Fig. 3c). This in part reflected the increase in CD3 cells and lymphoid follicles in the inflamed colon (Fig. 3, c and d). There was no increase in the actual density of Foxp3 cells in the T cell areas in inflamed vs uninflamed samples. By contrast there was a higher density of Foxp3 cells in the inflamed LP compared with controls. Together, the data suggest that inflammation is driving the accumulation of regulatory cells, particularly in effector sites. To analyze whether the accumulation of Foxp3 cells in inflamed IBD LP is a specific feature of CD or UC or is due to a general accumulation of Foxp3 cells in inflamed intestinal tissue, we compared the density of Foxp3 cells in colon sections of patients with IBD with those with diverticulitis, pseudomembranous colitis, or CMV-induced colitis (CMV) (Fig. 3, b d). In all cases we found an increased density of Foxp3 cells indicating that the accumulation of Foxp3 cells is driven by inflammation in the intestine and is not a specific feature of IBD. The presence of Foxp3 cells in patients with IBD argues against a simple lack of Foxp3 T R as a cause of the intestinal inflammation, but for ineffective activity of these cells, or nonresponsiveness to their activity, under conditions of chronic intestinal inflammation. To investigate whether there is an association of Foxp3 positive cells with IL-10 secretion within the human intestine, we stained human appendix for IL-10 and Foxp3. IL-10-producing cells were found in high density within the germinal center as well as in the subepithelial dome area (Fig. 3e). We show the presence of IL- 10-positive CD3 Foxp3 T R cells as well CD3 Foxp3 cells that are IL-10 negative but are in close contact with IL-10-positive CD3 Foxp3 cells (Fig. 3e). This indicates that some Foxp3 cells secrete IL-10 within the intestine but that these cells are frequently in close contact with IL-10-producing non-t cells (CD3 Foxp3 cells). Cure of colitis is dependent on IL-10 We have described the presence of Foxp3 CD4 CD25 T cells in both the secondary lymphoid organs and colonic LP during cure of experimental colitis, suggesting that regulation occurs at both sites. We next decided to further investigate the mechanism by which CD4 CD25 T cells cure colitis. Again, we transferred CD4 CD25 cells into animals with established T cell-induced colitis. However, if the transfer of CD4 CD25 cells was combined FIGURE 2. Presence of Foxp3 CD4 CD25 T cells in the colons of mice with colitis and mice cured of colitis. rag-1 / mice were injected with 4 10 5 wild-type CD45.2 CD4 CD45RB high T cells. Four weeks after the T cell transfer, wasting disease and colitis were evident, and a second transfer of 1 10 6 congenic CD45.1 CD4 CD25 T cells was performed. Sections of colon taken either 2 (a) or10(b) wk after the second T cell transfer were stained with H&E, Abs to CD4 and CD45.1, or Abs to Foxp3 and CD45.1. DAPI counterstaining was performed to visualize the tissue structure. E indicates epithelium. The presented micrographs are representative of three to five mice analyzed.

5856 Foxp3 AND IL-10-SECRETING CD4 CD25 T R IN CURE OF COLITIS FIGURE 3. Presence of Foxp3-positive cells in the mucosa and intestinal lymphoid follicles of patients with IBD. Colon samples from normal controls and patients with ulcerative colitis (UC), Crohn s disease (CD), non-ibd inflammations of the colon (diverticulitis (D), pseudomembranous colitis (PC), and CMV-induced colitis (CMV)) were analyzed for CD3, CD4, and Foxp3. Sections from tonsil were analyzed for CD4 and Foxp3. a, Costaining for CD4 and Foxp3 on human tonsil. Overview ( 100) and high-power magnification. b, CD3 and Foxp3 staining on colon tissue. c, Density of CD3 and Foxp3 cells within colon. Numbers of cells were quantified per area at 400 magnification. Each data point represents one patient. d, Density of Foxp3 cells within colonic LP, as well as T and B cell areas of mucosa-associated lymphoid tissue. Each data point represents one patient. e, Costaining of Foxp3 and IL-10 on human appendix tissue. Left, Costaining of Foxp3, IL-10, and DAPI showing IL-10-positive cells within the germinal center (GC) and subepithelial dome (SED) close to the epithelium (E). Detail of Foxp3 IL-10 cells within the subepithelial dome area are also shown. Right, Costaining of Foxp3, IL-10, and CD3. Detail shows IL-10 CD3 Foxp3 cells as well CD3 Foxp3 cells that are in close contact with IL-10 CD3 Foxp3 cells. with injection of a neutralizing anti-il-10r mab, mice continued to lose weight and remained colitic (Fig. 4). Many different cell types have been shown to be able to produce IL-10. To investigate whether the IL-10 needs to be secreted by the CD4 CD25 T cell progeny a third group of colitic mice received CD4 CD25 T cells from IL-10 / mice. Interestingly, although CD4 CD25 IL-10 / T cells were less effective at controlling intestinal inflammation than wild-type CD4 CD25 cells they did lead to some amelioration of disease (Fig. 4). The data demonstrates that the presence of IL-10 is required for treatment of colitis, and also suggests that functionally relevant IL-10 may derive from both T R and non-t R sources. However, wild-type CD4 CD25 cells were equally effective at curing colitis induced by wild-type or IL-10 / CD4 CD45RB high cells, suggesting that IL-10 production by CD4 CD45RB high progeny is not critical for cure of colitis.

The Journal of Immunology 5857 FIGURE 4. Cure of colitis depends on the presence of IL-10 from CD4 CD25 T cells, as well as other cell types. Colitis was induced by transfer of 4 10 5 CD4 CD45RB high T cells into CB17 SCID mice. After development of colitis, mice were injected with 1 10 6 CD4 CD25 T cells from wild-type mice together with anti-il-10r mab or isotype control Abs. Further groups of colitic mice received either CD45RB high or CD4 CD25 T cells from IL-10 / mice. Sections of colon were scored for the severity of colitis. Score values above 2 indicate mice with pronounced colitis. Data are pooled from four independent experiments. IL-10-producing CD4 CD25 T cells enrich within the colon To further investigate the source of IL-10 and the frequency of IL-10-producing T cells within the CD4 CD25 T cell progeny during cure of colitis, we used the congenic system described above. T cells were isolated from colitic and cured mice and activated using PMA/ionomycin. This permitted analysis of the potential of the progeny of the CD4 CD45RB high cells, and the progeny of the CD4 CD25 cells, to produce IL-10 and IFN- (Fig. 5). A significant proportion of T cells derived from the CD4 CD45RB high progeny produced IFN-, irrespective of whether they were isolated from spleen, MLN, or colonic LP (Fig. 5). Indeed the frequency of IFN- cells among the CD4 CD45RB high progeny in the LP was similar in colitic mice and mice with T R - mediated resolution of colitis (Fig. 5b). Within this population there was no significant induction of IL-10 production, indicating that cure of colitis does not involve immune deviation of the colitogenic T cell population into one producing immune suppressive cytokines (Fig. 5b). A significantly higher proportion of the progeny of CD4 CD25 cells produced IL-10 than the progeny of CD4 CD45RB high cells ( p 0.05). Strikingly, IL-10-producing CD4 CD25 progeny were selectively enriched within the colonic LP (Fig. 5b). To test whether the enrichment of IL-10-producing cells within the colonic LP was a general feature of CD4 CD25 T cells, or due to the specific inflammatory conditions present during the cure of colitis, we analyzed IL-10 production by CD4 CD25 T cells from the colons of wt mice. Consistent with the results obtained in the T cell transfer model, we were able to identify IL-10-producing CD4 CD25 cells in wild-type mice that selectively enriched within the colonic LP (data not shown). We were also able to show that in wt mice the IL-10 secreting T cells isolated from the colonic LP expressed Foxp3 (Fig. 6). Discussion In previous studies, we and others have shown that transfer of CD4 CD25 T R cells to colitic mice is sufficient to resolve the inflammatory response leading to restoration of normal intestinal architecture (19, 20). Here, we have analyzed the anatomical location and mechanism by which small numbers of T R cells are able to overcome sustained activation of the innate and adaptive immune response. Using expression of Foxp3 protein as a marker of bona fide naturally arising T R cells, we show that cure of colitis involves the accumulation of Foxp3 T R cells in the secondary lymphoid tissue as well as in the colonic LP. Such cells are also present in the intestine of normal mice and are increased in number in the intestine of patients with IBD. We also show that cure of colitis by CD4 CD25 T R cells involves an IL-10-dependent mechanism, and that CD4 CD25 T R cells are able to secrete IL-10. Strikingly, IL-10-producing CD4 CD25 T cells were most prominent in the colonic LP of both colitic mice and unmanipulated wild-type mice suggesting further functional specialization of T R cells in effector sites. Although naturally occurring T R cells enrich within the CD4 CD25 subset, CD25 itself is a marker of activation and therefore unsuitable as an indicator of T cells with regulatory potential. However, the transcription factor, Foxp3, is highly expressed among the CD4 CD25 T cell pool, and is in fact required for regulatory T cell development and function (12 14). Foxp3 is therefore a useful and specific marker for naturally occurring T R. Elegant studies by Fontenot et al. (23) using mice with a GFP-Foxp3 fusion protein-reporter knockin allele have shown that approximately half of the CD4 CD25 population isolated from lymph nodes express Foxp3. However, detailed analysis of Foxp3 expression in situ, and in pathogenic situations, was not performed in that study. Our results using in situ analysis with a Foxp3 polyclonal Ab showed that Foxp3 cells were located in the T cell areas in close contact with APCs. Foxp3-expressing CD4 CD25 T cells were also found in the colon under normal physiological conditions suggesting an in situ role for T R cells in intestinal homeostasis. Transfer of naive CD45RB high cells into immunodeficient mice leads to the development of a severe colitis, but it is now wellestablished that cotransfer of CD4 CD25 T R can prevent disease. More recently, we showed that CD4 CD25 T R can also bring an existing inflammatory response under control. It can be envisaged that the focus of T R activity may differ in these two situations, with the need for T R activity in the periphery being greater during cure of colitis when T cells have already become activated and migrated into peripheral effector sites. Consistent with this, during and after cure of colitis the progeny of the CD4 CD25 cells were found both in the secondary lymphoid organs and the LP and follicles of the inflamed colon (20). CD4 CD25 T R have also been shown to localize to colonic follicles when cotransferred with CD4 T cells reactive to bacterially expressed OVA (28). Using Foxp3 as a more accurate indicator of regulatory activity, we now show that Foxp3 cells are also found in both the lymphoid tissue and intestine of colitic mice. By contrast with normal physiological conditions, where Foxp3 cells account for 20% of CD4 CD25 cells in the colon, during cure of experimental colitis, Foxp3 cells accounted for some 50% of the CD25 progeny. This could indicate that the accumulation of Foxp3 CD4 CD25 T cells may be in part driven by intestinal inflammation, or may simply reflect an even distribution of the transferred splenic CD4 CD25 T cells in all of the organs analyzed. We have also investigated the role of IL-10 in the cure of colitis by CD4 CD25 T cells. Our previous studies showed that mice typically started to recover, by around two weeks after T R cell transfer. At this time point, effector T cells, as well as other inflammatory cells, greatly outnumber the CD4 CD25 progeny. This indicates that CD4 CD25 T R suppressor mechanisms are locally very potent. This potency may be a consequence of the

5858 Foxp3 AND IL-10-SECRETING CD4 CD25 T R IN CURE OF COLITIS FIGURE 5. Accumulation of the IL-10-producing progeny of CD4 CD25 T cells within the colon. rag- 1 / mice were injected with 4 10 5 wild-type CD45.2 CD4 CD45RB high T cells. After development of colitis, mice received a second transfer of 1 10 6 congenic CD45.1 CD4 CD25 T cells. After 4 wk, the ability of CD4 CD45RB high (n 6) and CD4 CD25 (n 6) progeny to produce IL-10 and IFN- was analyzed. Lymphocytes were prepared from spleen, MLN, and the colonic LP and stimulated with PMA/ionomycin and brefeldin A. The results of two independent experiments are pooled. a, Representative FACS plot showing preferential IL-10 production by LP CD4 CD25 T cell progeny (CD45.1 ) and preferential IFN- production by the CD4 CD45RB high T cell progeny (CD45.1 ). b, Production of IL-10 and IFN- by CD4 CD25 T cell progeny and comparison of IL-10 and IFN- production by CD4 CD45RB high T cell progeny in the presence or absence of CD4 CD25 T cells. Data are shown for spleen, MLN, and LP. Significance was tested using the Mann-Whitney U test; n.s., not significant. secretion of high concentrations of immunosuppressive cytokines, or instruction of effector cells to produce such cytokines. Indeed, previous studies have demonstrated the necessity of IL-10 for the cure of T cell-induced colitis, and of CD4 CD25 T cell-derived IL-10 for inhibition of colonic inflammation and dysplasia (19, 29). Our own results confirm IL-10 is required for the resolution of established colitis, and furthermore demonstrate that a proportion of the CD4 CD25 cell progeny in the colons of treated mice produced IL-10. Similarly, recent studies have demonstrated the presence of IL-10-producing CD4 CD25 T cells in prediabetic and Leishmania major lesions, and in the CNS in EAE (30 32). However, we also show that IL-10 / CD4 CD25 T cells are, although less potent, able to cure colitis. It would appear that although T R are a major source of the IL-10 required for cure of colitis, other cell types, possibly under the instruction of T R, can make an important contribution. Indeed, experiments investigating the protective role of IL-10 in schistosomiasis have shown that both innate immune cells and T cells contribute to IL-10 production (33). Many different cell types, including epithelial cells, macrophages, DC, and other T cells subsets, have been shown to produce IL-10. For example, naive T cells can differentiate into IL-10 producers with regulatory function both in vitro and in vivo (2). Importantly, such cells are also able to cure colitis in the T cell transfer model (21). However, we do not consider the naive T cell population to be an essential source of IL-10 in our model. This is based on the finding that colitis induced by IL-10 / CD45RB high T cells was efficiently cured by CD4 CD25 T R cells. Foxp3 T R cells can also arise from naive progenitors in vivo following chronic exposure to low doses of Ag (34) or in vitro when activated in the presence of TGF- (24, 35 37). However, we found no evidence that resolution of intestinal inflammation, at least in the T cell transfer model, was associated with significant immune deviation of CD4 CD45RB high progeny into either Foxp3 - or IL-10-producing T R cells. Cure of colitis was also not

The Journal of Immunology 5859 FIGURE 6. IL-10 secretion by Foxp3 cells in the LP of wild-type mice. Lamina propria and spleen cell suspensions were restimulated with PMA/ionomycin as described in Materials and Methods. a, Representative dot plots showing Foxp3 expression against IL-10 or an isotype control in spleen and LP of B6 SJL CD45 congenic mice. Plots are gated on CD4 cells. The numbers indicate the percentage of IL-10 cells in the Foxp3 or Foxp3 populations. b, Percentage of IL-10-secreting cells in the Foxp3 (filled symbols) and Foxp3 (open symbols) populations from spleen (Sp) and LP CD4 lymphocytes (LPL) from B6 SJL CD45 congenic mice. Each symbol represents data from an individual mouse. In all cases, the isotype control stained 1% of total cells. Similar results were obtained in an experiment using BALB/c mice. dependent on a reduction in the proportion of IFN- -secreting cells among the CD4 CD45RB high progeny, although, as reported previously, the total number of CD4 T cells present in the colon was greatly reduced (20). We have previously demonstrated that IL-10 is not required for the prevention of colitis by CD4 CD25 T R. However, when the whole CD4 CD45RB low fraction is transferred instead of CD4 CD25 T R, prevention of colitis becomes dependent on IL-10. In this situation, T R -derived IL-10 appears to be essential for the control of colitogenic cells contained within the Ag-experienced CD45RB low pool, but not for control of naive T cells (27). The finding that IL-10 is essential for cure of colitis, where a large population of Ag-experienced cells are present, is consistent with this. We have shown that the IL-10-producing subset of CD25 selectively enriches within the colon of cured mice. The population of T R used in our model was isolated from the spleen and as such expressed only low levels of IL-10 upon transfer. It is therefore possible that the gut environment conditioned the T R to further differentiate into IL-10-producing cells. Alternatively, the accumulation of IL-10 T R in the colon could be attributed to the preferential expansion and homing of a minor subset of IL-10 producers contained within the transferred population. The inability of CD4 CD25 cells isolated from peripheral lymphoid organs to secrete IL-10 in vitro has led to the notion that naturally arising Foxp3 T R cells function via cytokine independent mechanisms (38). However, our finding that IL-10 Foxp3 cells are enriched within tissue sites illustrates the problems with extrapolating observations in vitro to predicted function in vivo. The identification of IL-10-producing CD4 CD25 T cells in the normal colon suggests a constitutive role for those cells in the prevention of intestinal inflammatory responses. Our data is supported by the earlier observation by Cong et al. (39) that bacterially reactive IL-10- secreting CD4 T cells are present in the colons of normal mice. However, that study did not establish whether such bacterially reactive cells belonged to the naturally occurring Foxp3 T R pool, or acquired regulatory activity in the periphery. We now show that IL-10-secreting CD4 CD25 T R in the normal colon are contained within the Foxp3 subset. It is however likely that under certain conditions, other IL-10-producing T R cells that do not express Foxp3 may be induced (40). Human IBDs consist of two dominant disease subtypes. CD is largely Th1 in nature (41), while IL-5-, and IL-13-producing T or NKT cells are found in UC (42). Although there is evidence for T cell-mediated immune dysregulation in human IBD, there is limited evidence that disease results from a primary lack or dysfunction of T R cells. However, clear evidence that a lack of functionally sufficient T R cells can lead to chronic intestinal inflammation in humans does come from the study of patients with immune polyendocrine X-linked enteropathy syndrome (17, 18). CD4 CD25 Foxp3 mrna expressing T cells have recently been isolated from human intestinal tissue samples, and CD4 CD25 T cells from the colons of IBD patients have been shown to be suppressive in vitro (43, 44). Our data show that Foxp3-positive cells are present within the noninflamed LP, and are also present in increased numbers in patients with acute UC and CD. The increase in Foxp3 cell density was seen largely in the LP, rather than in the T cell areas of isolated lymphoid follicles. This can be explained by considering the T cell areas of the isolated lymphoid follicles to be sites of induction of immune responses, analogous to those in the lymph node. Therefore, during an active inflammatory response, T R may be expected to be preferentially recruited to the site of inflammation. A recent study also found an increase in CD25 Foxp3 cells in the colon of UC and CD patients, although this increase was modest compared with that seen in diverticulitis (45). In our study, a similar increase in Foxp3 cells is seen in UC, CD, and diverticulitis, but also in CMV colitis and pseudomembranous colitis, strongly suggesting that chronic intestinal inflammation is not simply a consequence of the absence of Foxp3 CD4 T R cells at the site of inflammation. Whether the T R cells present have, at least in some patients, impaired intrinsic immunosuppressive activity, or whether the inflamed tissue environment is resistant to immunosuppression by T R cells remains to be investigated. In any case, our data on human Foxp3 cells supports the hypothesis that intestinal immune regulation in mice and humans may share common features. Consequently, further investigation of the mechanisms by which T R can cure experimental colitis may give us insight into how regulatory T cell function might be enhanced in human IBD.

5860 Foxp3 AND IL-10-SECRETING CD4 CD25 T R IN CURE OF COLITIS Acknowledgments We thank animal facility personnel, Liz Darley, Sandy Laue, and Martina Fuegenschuh for histology, Nigel Rust for cell sorting, and Kevin Maloy for critical reading of the manuscript. Disclosures The authors have no financial conflict of interest. References 1. Maloy, K. J., and F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2: 816 822. 2. O Garra, A., P. L. Vieira, P. Vieira, and A. E. Goldfeld. 2004. IL-10-producing and naturally occurring CD4 Tregs: limiting collateral damage. J. Clin. Invest. 114: 1372 1378. 3. Sakaguchi, S. 2004. Naturally arising CD4 regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531 562. 4. Coombes, J. L., N. J. Robinson, K. J. Maloy, H. H. Uhlig, and F. Powrie. 2005. Regulatory T cells and intestinal homeostasis. Immunol. Rev. 204: 184 194. 5. Read, S., V. Malmstrom, and F. Powrie. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25 CD4 regulatory cells that control intestinal inflammation. J. Exp. Med. 192: 295 302. 6. Kriegel, M. A., T. Lohmann, C. Gabler, N. Blank, J. R. Kalden, and H. M. Lorenz. 2004. Defective suppressor function of human CD4 CD25 regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 199: 1285 1291. 7. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A. Hafler. 2004. Loss of functional suppression by CD4 CD25 regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971 979. 8. Baecher-Allan, C., V. Viglietta, and D. A. Hafler. 2004. Human CD4 CD25 regulatory T cells. Semin. Immunol. 16: 89 98. 9. Kukreja, A., G. Cost, J. Marker, C. Zhang, Z. Sun, K. Lin-Su, S. Ten, M. Sanz, M. Exley, B. Wilson, et al. 2002. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109: 131 140. 10. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-tnf therapy. J. Exp. Med. 200: 277 285. 11. Bacchetta, R., L. Passerini, E. Gambineri, M. Dai, S. E. Allan, L. Perroni, F. Dagna-Bricarelli, C. Sartirana, S. Matthes-Martin, A. Lawitschka, et al. 2006. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. 116: 1713 1722. 12. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4 CD25 regulatory T cells. Nat. Immunol. 4: 330 336. 13. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T Cell development by the transcription factor FOXP3. Science 299: 1057 1061. 14. Khattri, R., T. Cox, S. A. Yasayko, and F. Ramsdell. 2003. An essential role for Scurfin in CD4 CD25 T regulatory cells. Nat. Immunol. 4: 337 342. 15. Godfrey, V. L., J. E. Wilkinson, and L. B. Russell. 1991. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am. J. Pathol. 138: 1379 1387. 16. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, J. E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27: 68 73. 17. Wildin, R. S., F. Ramsdell, J. Peake, F. Faravelli, J. L. Casanova, N. Buist, E. Levy-Lahad, M. Mazzella, O. Goulet, L. Perroni, et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27: 18 20. 18. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20 21. 19. Liu, H., B. Hu, D. Xu, and F. Y. Liew. 2003. CD4 CD25 regulatory T cells cure murine colitis: the role of IL-10, TGF-, and CTLA4. J. Immunol. 171: 5012 5017. 20. Mottet, C., H. H. Uhlig, and F. Powrie. 2003. Cutting edge: cure of colitis by CD4 CD25 regulatory T cells. J. Immunol. 170: 3939 3943. 21. Foussat, A., F. Cottrez, V. Brun, N. Fournier, J. P. Breittmayer, and H. Groux. 2003. A comparative study between T regulatory type 1 and CD4 CD25 T cells in the control of inflammation. J. Immunol. 171: 5018 5026. 22. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigenspecific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455 1465. 23. Fontenot, J. D., J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. Y. Rudensky. 2005. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329 341. 24. Wan, Y. Y., and R. A. Flavell. 2005. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc. Natl. Acad. Sci. USA 102: 5126 5131. 25. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312: 548 551. 26. Coffman, R. L. 1982. Surface antigen expression and immunoglobulin gene rearrangement during mouse pre-b cell development. Immunol. Rev. 69: 5 23. 27. Asseman, C., S. Read, and F. Powrie. 2003. Colitogenic Th1 cells are present in the antigen-experienced T cell pool in normal mice: control by CD4 regulatory T cells and IL-10. J. Immunol. 171: 971 978. 28. Watanabe, T., M. Yamori, T. Kita, T. Chiba, and Y. Wakatsuki. 2005. CD4 CD25 T cells regulate colonic localization of CD4 T cells reactive to a microbial antigen. Inflamm. Bowel Dis. 11: 541 550. 29. Erdman, S. E., V. P. Rao, T. Poutahidis, M. M. Ihrig, Z. Ge, Y. Feng, M. Tomczak, A. B. Rogers, B. H. Horwitz, and J. G. Fox. 2003. CD4 CD25 regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 63: 6042 6050. 30. McGeachy, M. J., L. A. Stephens, and S. M. Anderton. 2005. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4 CD25 regulatory cells within the central nervous system. J. Immunol. 175: 3025 3032. 31. Herman, A. E., G. J. Freeman, D. Mathis, and C. Benoist. 2004. CD4 CD25 T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199: 1479 1489. 32. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach, and D. L. Sacks. 2002. CD4 CD25 regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502 507. 33. Hesse, M., C. A. Piccirillo, Y. Belkaid, J. Prufer, M. Mentink-Kane, M. Leusink, A. W. Cheever, E. M. Shevach, and T. A. Wynn. 2004. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J. Immunol. 172: 3157 3166. 34. Apostolou, I., and H. von Boehmer. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199: 1401 1408. 35. Cobbold, S. P., R. Castejon, E. Adams, D. Zelenika, L. Graca, S. Humm, and H. Waldmann. 2004. Induction of foxp3 regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J. Immunol. 172: 6003 6010. 36. Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 2003. Conversion of peripheral CD4 CD25 naive T cells to CD4 CD25 regulatory T cells by TGF- induction of transcription factor Foxp3. J. Exp. Med. 198: 1875 1886. 37. Fantini, M. C., C. Becker, G. Monteleone, F. Pallone, P. R. Galle, and M. F. Neurath. 2004. Cutting edge: TGF- induces a regulatory phenotype in CD4 CD25 T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172: 5149 5153. 38. Bluestone, J. A., and A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253 257. 39. Cong, Y., C. T. Weaver, A. Lazenby, and C. O. Elson. 2002. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J. Immunol. 169: 6112 6119. 40. Vieira, P. L., J. R. Christensen, S. Minaee, E. J. O Neill, F. J. Barrat, A. Boonstra, T. Barthlott, B. Stockinger, D. C. Wraith, and A. O Garra. 2004. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4 CD25 regulatory T cells. J. Immunol. 172: 5986 5993. 41. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521 533. 42. Fuss, I. J., F. Heller, M. Boirivant, F. Leon, M. Yoshida, S. Fichtner-Feigl, Z. Yang, M. Exley, A. Kitani, R. S. Blumberg, et al. 2004. Nonclassical CD1drestricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113: 1490 1497. 43. Makita, S., T. Kanai, S. Oshima, K. Uraushihara, T. Totsuka, T. Sawada, T. Nakamura, K. Koganei, T. Fukushima, and M. Watanabe. 2004. CD4 CD25 bright T cells in human intestinal lamina propria as regulatory cells. J. Immunol. 173: 3119 3130. 44. Kelsen, J., J. Agnholt, H. J. Hoffmann, J. L. Romer, C. L. Hvas, and J. F. Dahlerup. 2005. FoxP3 CD4 CD25 T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn s disease. Clin. Exp. Immunol. 141: 549 557. 45. Maul, J., C. Loddenkemper, P. Mundt, E. Berg, T. Giese, A. Stallmach, M. Zeitz, and R. Duchmann. 2005. Peripheral and intestinal regulatory CD4 CD25 high T cells in inflammatory bowel disease. Gastroenterology 128: 1868 1878.